Notice Number: NOT-CA-20-042
Release Date: April 10, 2020
First Available Due Date: April 14, 2020
Expiration Date: June 26, 2020
PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)
PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
National Cancer Institute (NCI)
The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and the effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on cancer, and vice versa. Topics of specific interest to NCI include understanding the basic mechanisms of interaction between SARS-CoV-2 and cancer cells, co-morbidities of cancer and SARS-CoV-2 infection (especially in disparately affected patient populations), and the impacts on treatment and clinical outcomes of SARS-CoV-2 infected persons in the context of cancer.
The COVID-19 pandemic is an urgent health emergency (as defined by CDC and WHO). Persons diagnosed with COVID-19 have reported symptoms such as fever, cough, shortness of breath, fatigue, myalgias, headache, sore throat, abdominal pain, and diarrhea. Patients admitted to the hospital generally have pneumonia and abnormal chest imaging. Complications include acute respiratory failure and acute respiratory distress syndrome, which appears to be a significant predictor of mortality. The severity of illness and course of the infection is heterogeneous and appears to be more severe in the elderly and in individuals with underlying comorbidities including cancer. Due to the presence of malignancy and the effects of anticancer treatments, cancer patients often exist in a systemic immunosuppressive state and are more susceptible to many types of infection. Therefore, these patients might be at an increased risk of COVID-19 and have a poorer prognosis. To date, SARS-CoV-2 infection and COVID-19 have not significantly impacted children, a pattern atypical for most viral respiratory diseases.
To better understand the impact of SARS-CoV-2 infection and its impact on cancer patients’ disease progression, response to therapy, care delivery, or survivorship, the NCI encourages the submission of applications to either PA-18-935, Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional) or to PA-18-591, Administrative Supplements to Existing Grants and Cooperative Agreements (Parent Admin Supp – Clinical Trial Optional). Of particular interest are studies that take advantage of unique cancer model systems or analytical tools to study the consequences of SARS-CoV-2 infection and COVID-19 disease progression. Supported research is expected to inform future efforts to diagnose, prevent, mitigate, or treat this viral infection in persons with cancer (or pre-cancer), undergoing treatment for cancer, or are in remission.
Possible research interests include, but are not limited to, the following areas focused on the intersection of cancer research and infection with SARS-CoV-2 or illness associated with COVID-19 disease:
Applications may request funds for the collection of samples from human cancer cohorts of individuals with COVID-19 disease or evidence of SARS-CoV-2 infection, and/or development of novel cancer model systems to expose animals and cells to SARS-CoV-2.
Applicants are strongly encouraged to contact the NCI Program Director of the parent award to discuss potential applications and whether urgent competitive revision applications or administrative supplement requests are more appropriate for the proposed research.
Application and Submission Information
Applications in response to this NOSI must be submitted using the following target funding opportunity announcement or subsequent reissued equivalent.
Administrative supplements proposed through PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) must be within the general scope of the research or training that is already supported. Eligible activity codes for applications to PA-18-591 are limited to the mechanisms listed in PA-18-591.
Eligible activity codes for applications proposed through PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements Clinical Trial Optional) are limited to the following mechanisms: P01; P30; P50; R00; R01; R33; R35; R37; U01; U19; U24; and U54.
To be eligible for an Urgent Competitive Revision or an Administrative Supplement through this NOSI and the respective FOA, the parent award on which the revision application is based must:
Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact and discuss their proposed research/aims with NCI Program Directors of the parent award before writing and submitting their competitive revision and/or administrative supplement applications to allow for the determination of appropriateness and interest of the NCI in any related proposed research.
Please direct general inquiries to:
Please direct financial/budgetary inquiries to:
Chief Grants Management OfficerNCI)
Please direct scientific/programmatic inquiries to:
The NCI Program Director who has stewardship of the parent award for which you would like to submit a competitive revision or administrative supplement application.